Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VESICARE LS

SOLIFENACIN SUCCINATE

Standard Dose
1MG/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview VESICARE LS is listed in Drugs@FDA under application 209529 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient SOLIFENACIN SUCCINATE Form and strength SUSPENSION;ORAL - 1MG/ML Sponsor ASTELLAS Submission history Latest submission status date: 2020-05-26 00:00:00.

Structured Monograph

Clinical summary

Approval overview VESICARE LS is listed in Drugs@FDA under application 209529 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient SOLIFENACIN SUCCINATE Form and strength SUSPENSION;ORAL - 1MG/ML Sponsor ASTELLAS Submission history Latest submission status date: 2020-05-26 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.